From: Economic burden of varicella in Europe in the absence of universal varicella vaccination
Age group | Primary care visits | Hospitalizations | Prescriptions | OTC medications | Work loss caregivers | Work loss patients | Work loss deaths | Proportion of total cost |
---|---|---|---|---|---|---|---|---|
<5y | € 51,939,569 | € 29,121,301 | € 18,648,121 | € 20,541,844 | € 193,314,712 | NA | NA | 47.32% |
5-9y | € 30,605,288 | € 8,138,576 | € 10,516,603 | € 11,741,757 | € 105,800,000 | NA | NA | 25.17% |
10-14y | € 7,830,211 | € 2,117,755 | € 2,853,437 | € 826,043 | € 24,659,029 | NA | NA | 5.78% |
15-19y | € 2,936,218 | € 1,940,903 | € 1,071,301 | € 585,661 | € 8,938,000 | NA | NA | 2.34% |
20-39y | € 7,259,423 | € 9,407,695 | € 2,517,461 | € 1,362,976 | NA | € 75,435,180 | € 57,955 | 14.49% |
40-64y | € 2,413,798 | € 3,123,022 | € 961,981 | € 615,262 | NA | € 25,146,631 | € 164,349 | 4.89% |
Total | € 102,984,507 | € 53,849,251 | € 36,568,905 | € 35,673,544 | € 332,711,741 | € 100,581,811 | € 222,303 | 100.00% |